戈沙妥珠单抗（IMMU-132）治疗难治性子宫浆液性癌：一例报告
Sacituzumab Govitecan (IMMU-132) in treatment-resistant uterine serous carcinoma: A case report.
作者信息
Han Chanhee, Bellone Stefania, Schwartz Peter E, Govindan Serengulam V, Sharkey Robert M, Goldenberg David M, Santin Alessandro D
机构信息
Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, United States.
Immunomedics, Inc., 300 The American Road, Morris Plains, NJ 07950, United States.
出版信息
Gynecol Oncol Rep. 2018 May 23;25:37-40. doi: 10.1016/j.gore.2018.05.009. eCollection 2018 Aug.
BACKGROUND
Uterine serous carcinoma (USC) is a biologically aggressive variant of uterine cancer. Effective treatment options for recurrent, chemotherapy-resistant USC are extremely limited.
CASE
We describe a 74-year-old woman with recurrent and widespread treatment-resistant disease, who experienced a dramatic response to sacituzumab govitecan, a novel antibody-drug conjugate (ADC) targeting human trophoblast-cell-surface antigen (TROP-2), after failing multiple chemotherapy and immunotherapy. The impressive clinical response (66% reduction of target lesions by RECIST 1.1 with a duration response of over 10 months) was confirmed with serial CT scans in the absence of significant adverse events.
CONCLUSION
Sacituzumab govitecan may present a new treatment option for recurrent USC patients harboring Trop-2+ tumors resistant to chemotherapy. Clinical trials with sacituzumab govitecan are warranted.
背景
子宫浆液性癌（USC）是子宫癌中一种具有生物学侵袭性的变体。对于复发性、化疗耐药的USC，有效的治疗选择极为有限。
病例
我们描述了一名74岁患有复发性广泛性耐药疾病的女性，在多次化疗和免疫治疗失败后，对戈沙妥珠单抗（一种靶向人滋养层细胞表面抗原（TROP - 2）的新型抗体药物偶联物（ADC））产生了显著反应。在没有明显不良事件的情况下，通过系列CT扫描证实了令人印象深刻的临床反应（根据RECIST 1.1标准，靶病灶减少66%，反应持续时间超过10个月）。
结论
戈沙妥珠单抗可能为携带对化疗耐药的Trop - 2+肿瘤的复发性USC患者提供一种新的治疗选择。有必要开展戈沙妥珠单抗的临床试验。
Zotero 插件